Skip to main content
EBS logo

EBS · Emergent BioSolutions Inc.

$7.63 -0.06 (-0.78%) At close · Jul 17
Market Cap
$393.68M
Shares
51.60M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Joseph Papa $5,321,147
Richard S. Lindahl $2,708,723
Coleen Glessner $1,664,258
Simon Lowry $1,471,276
Paul Williams $1,391,158
Fiscal 2024
Executive Total
Joseph Papa $5,862,562
Richard S. Lindahl $2,311,320
Coleen Glessner $2,053,213
William Hartzel $1,714,261
Paul Williams $1,675,687
Jennifer Fox $1,189,933
Haywood Miller $218,750
Fiscal 2023
Executive Total
Robert Kramer $5,103,858
Richard S. Lindahl $2,178,980
Jennifer Fox $2,131,320
Adam Havey $2,010,487
Coleen Glessner $1,681,538
Paul Williams $1,063,639
Haywood Miller $766,667
Fiscal 2022
Executive Total
Robert Kramer $7,578,573
Adam Havey $3,621,626
Richard S. Lindahl $3,522,762
Atul Saran $3,504,868
Jennifer Fox $2,923,207
Fiscal 2021
Executive Total
Robert Kramer $6,932,076
Fuad El-Hibri $3,515,977
Richard S. Lindahl $2,197,585
Adam Havey $2,092,783
Atul Saran $2,070,344
Fiscal 2020
Executive Total
Robert Kramer $5,569,978
Fuad El-Hibri $3,213,484
Richard S. Lindahl $2,281,300
Adam Havey $2,175,528
Atul Saran $2,159,032
Fiscal 2019
Executive Total
Robert Kramer $3,693,821
Fuad El-Hibri $3,010,062
Richard S. Lindahl $1,877,497
Atul Saran $1,862,979
Adam Havey $1,845,367
Daniel J. Abdun-Nabi $633,322
Fiscal 2018
Executive Total
Daniel J. Abdun-Nabi $4,100,936
Fuad El-Hibri $2,970,218
Robert Kramer $2,396,747
Atul Saran $1,698,027
Corporate Development $1,698,027
Adam Havey $1,659,081
Richard S. Lindahl $1,612,453
Fiscal 2017
Executive Total
Daniel J. Abdun-Nabi $3,681,284
Fuad El-Hibri $2,567,482
Robert Kramer $1,712,371
Corporate Development $1,220,554
Adam Havey $1,158,295
Key facts CIK 1367644 CUSIP 29089Q105 13F (30d) 15 filings 15 filers Visit website Investor relations